Jasper Therapeutics (JSPR) Set to Announce Quarterly Earnings on Monday

Jasper Therapeutics (NASDAQ:JSPR) is expected to be releasing its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Jasper Therapeutics to announce earnings of ($0.06) per share and revenue of $6.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, analysts expect Jasper Therapeutics to post ($0.94) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $0.52 on Monday. The stock has a 50-day simple moving average of $0.60 and a two-hundred day simple moving average of $0.86. The firm has a market capitalization of $17.31 million, a P/E ratio of -0.33 and a beta of 3.30. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $2.42.

Analysts Set New Price Targets

JSPR has been the topic of a number of research analyst reports. Piper Sandler started coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price target on the stock. William Blair started coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating for the company. HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $7.33.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.